BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

FDA Approves Hope Pharmaceuticals Sodium Nitrite Injection for the Treatment of Cyanide Poisoning


4/13/2012 9:33:04 AM

SCOTTSDALE, AZ--(Marketwire - April 12, 2012) - Hope Pharmaceuticals (Hope) today announced that the United States Food and Drug Administration (FDA) approved Hope's Sodium Nitrite Injection for sequential use with sodium thiosulfate for the treatment of cyanide poisoning that is judged to be life-threatening.

Hope is the only supplier of Sodium Nitrite Injection that has been approved by the FDA.

Drugs containing sodium nitrite have been marketed in the United States without FDA approval and reportedly conform to an industry specification originally published prior to 1970 that lists only five tests.

FDA requires new drugs to meet more stringent quality requirements. The new FDA quality specification for sodium nitrite lists 27 tests, including many recent quality advancements such as limits on bacterial, chemical, degradation, and processing impurities. To comply with the new FDA-imposed requirements, Hope utilizes custom-manufactured, ultra-pure sodium nitrite as the ingredient in its FDA-approved medication.

"Critically-ill patients should receive only high quality medications," said Dr. Craig Sherman, Medical Director of Hope Pharmaceuticals. "Doctors should consider quality when choosing products from different manufacturers and choose an FDA-approved product whenever one is available. For the first time, doctors can choose to use an FDA-approved Sodium Nitrite Injection that complies with 2012 quality standards."

Hope's Sodium Nitrite Injection (NDC 60267-311-10) is packaged in a 10 mL vial containing 300 mg of sodium nitrite. It is now available in a carton containing one vial or in an FDA-approved kit (Nithiodote© [NDC 60267-812-00]) which also contains a vial of Sodium Thiosulfate Injection.

Hope's Sodium Nitrite Injection is approved for the treatment of children and adults. Prescribing information is available online at www.nitrite.com.

Hope Pharmaceuticals is a privately owned company located in Scottsdale, Arizona.


CONTACT:
Craig Sherman, M.D.
480-607-1970
Email Contact



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->